Topic: vision restoration
Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.
The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.
Johnson & Johnson Vision has secured FDA approval for a new laser eye surgery indication for its iDESIGN Refractive Studio system.
Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.
The mean increase in visual acuity now stands at 23 letters, well above the level deemed clinically meaningful by the FDA.
The AAV gene therapy was no better than placebo at improving vision at 48 weeks, leading GenSight to look to future updates to salvage the study.
Around half the patients in the higher-doses cohorts experienced vision improvements, encouraging Nightstar to move NSR-RPGR into phase 2.
GenSight Biologics has raised €22.5 million to prepare to bring gene therapy GS010 to market in the U.S. and Europe.
Novartis Chairman Joerg Reinhardt is talking down the chances of a smart lens project it began with Google yielding anything incredible in the next few years.
Allergan has bought gene therapy startup RetroSense Therapeutics to gain an early clinical candidate to treat the rare vision disorder retinitis pigmentosa (RP).